Skip to main content

Table 5 Incidence of diarrhea during the treatment period

From: Recommendations for the adjuvant use of the poly-antibiotic–resistant probiotic Bacillus clausii (O/C, SIN, N/R, T) in acute, chronic, and antibiotic-associated diarrhea in children: consensus from Asian experts

Symptoms

Per protocol population

Intention-to-treat population

Bacillus clausii (%)

Placebo (%)

RR; 95% CI

Bacillus clausii (%)

Placebo (%)

RR; 95% CI

Diarrhea

 - First week

10

30

0.333; 0.13–0.85*

9.3

30.8

0.301; 0.12–0.76**

 - Second week

4

8

0.5; 0.10–2.61

3.7

9.6

0.385; 0.08–1.90

  1. CI Confidence interval, RR Relative risk
  2. * p < 0.05; ** p < 0.01
  3. Adapted from: Nista EC, et al. Aliment Pharmacol Ther. 2004;20:1181–1188